Skip to main content
. 2017 Dec 7;4(5):702–706. doi: 10.1001/jamaoncol.2017.3361

Figure. Disposition of Patients in the UPWARD Study.

Figure.

SAF indicates safety analysis set; SRES, seizure-risk evaluation set.

aEvaluable patients were defined as those who completed at least 3 months of treatment with enzalutamide or who had at least 1 confirmed seizure in the 4-month initial treatment period.